That would make a nice Christmas present, Hurley. If Ixcell makes it to market, it could be bigger than MACI and Epicel combined. And more importantly, can help a lot of people in very dire straits. I don't think enough attention is being paid to Ixcell after the FDA meeting that requires further trials (which was not a surprise). It's hardly even mentioned but you know back at HQ, they are working on moving this forward. VCEL is starting to click on all cylinders and I think the next few quarters will confirm that. 4Q may not be a blowout as it takes some time to ramp up, but I think the '18 revenue projections on Yahoo of $70 million are way low. JMO, but I think holders will have a nice gift under their tree by next Christmas.